Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Preferred Stock Liabilities (2019 - 2020)

Keros Therapeutics (KROS) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $944000.0 as the latest value for Q1 2020.

  • For the quarter ending Q1 2020, Preferred Stock Liabilities changed N/A year-over-year to $944000.0, compared with a TTM value of $944000.0 through Mar 2020, changed N/A, and an annual FY2019 reading of $19.9 million, changed N/A over the prior year.
  • Preferred Stock Liabilities was $944000.0 for Q1 2020 at Keros Therapeutics, down from $19.9 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $19.9 million in Q4 2019 and bottomed at $944000.0 in Q1 2020.